Abbott Laboratories provided earnings guidance for the full-year 2023. For the year, the company expects diluted earnings per share from continuing operations under GAAP of $3.05 to $3.25. Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits and COVID-19 testing-related sales of around $2.0 billion.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
104.9 USD | +2.14% | +1.73% | -4.76% |
15/07 | Equity Markets Higher After Fed Chair Powell's Comments | MT |
15/07 | Equity Markets Rise Intraday After Fed Chair Powell's Comments | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.76% | 179B | |
-1.61% | 100B | |
-7.22% | 46.16B | |
+18.16% | 44.81B | |
+9.51% | 44.38B | |
+13.92% | 29.53B | |
+22.31% | 25.83B | |
-6.96% | 23.97B | |
+4.16% | 22.5B | |
-8.47% | 22.11B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Abbott Laboratories Provides Earnings Guidance for the Full-Year 2023